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The role of the conserved residue Tyr105 in class A b-lactamases has been
the subject of investigation using both structural studies and saturation
mutagenesis. Both have shown that while it does not need to be strictly
conserved for activity, it is important for substrate recognition. With this
in mind we determined the crystal structure of Toho1 b-lactamase at 15 K
to 1.10 A resolution in complex with penicillin. As expected a ring-opened
penicillin molecule bound to Ser70 the catalytic nucleophile, can clearly be
seen in electron density in the active site. In addition to the trapped peni-
cillin, however, are two additional intact ring-closed penicillin molecules,
captured by the enzyme through noncovalent interactions at the edge of
the active site.
Penicillin, a b-lactam antibiotic, was first observed by
Alexander Fleming in 1928 when he saw that mold
growing on an accidentally contaminated Petri dish
destroyed the bacteria surrounding it [1]. This discov-
ery changed the course of medical history. Unfortu-
nately, however, resistant bacteria have been evolving
alongside antibiotic agents long before their discovery
by humans [2]. Bacteria have obtained resistance to b-
lactam antibiotics in various ways, but most com-
monly by their expression of b-lactamases. Despite
evolving resistance to b-lactam antibiotics they remain
the most widely used class due to their low toxicity.
This is due to the fact that they interact with bacterial
penicillin binding proteins (PBPs) which are absent in
humans. PBPs are enzymes involved in the
construction of the bacterial cell wall. b-lactams are
able to form stable acyl-enzyme complexes with PBPs,
rendering them inactive, unable to maintain and con-
struct the cell wall, ultimately causing cell lysis. As
there is no human counterpart of this enzyme, and dis-
ruption of its activity is fatal to the bacterial cell, it is
important that we continue to develop our understand-
ing of how b-lactam antibiotics are bound and inacti-
vated by b-lactamase enzymes [3,4].
b-lactamase enzymes are a family of hydrolytic
enzymes expressed by resistant bacteria. They can be
divided into four distinct classes (A–D) based on amino
acid sequence identity [5]. Classes A, C and D employ a
catalytic serine residue to hydrolyze the b-lactam mole-
cule by formation and release of an acyl-enzyme
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intermediate (Fig. 1, stage 3). Class B b-lactamases uti-
lize metal ions at the active site, enabling a nucleophilic
hydroxide to break the b-lactam bond. Typical class A
b-lactamases are TEM, SHV and the emergent
extended-spectrum b-lactamase (ESBL) CTX-M
enzymes. These class A CTX-M ESBLs are often found
in clinical isolates associated with intra-abdominal and
urinary tract infections from highly virulent bacteria.
Infection with bacteria that express CTX-M ESBLs leads
to treatment problems in many clinical settings and dra-
matically increases mortality rate due to their broad sub-
strate profile. ESBLs exhibit increased hydrolytic activity
against the first, second, and third generation extended-
spectrum cephalosporins and monobactams [5–11]. The
Toho-1 b-lactamase is a CTX-M-type ESBL on the basis
of its amino acid sequence and its broad activity against
the extended-spectrum cephalosporins. Toho-1 is com-
posed of 262 amino acid residues and made up of two
highly conserved domains (a/b and a). The active site
cavity is formed at their interface.
Wild-type b-lactamases rapidly hydrolyze and release
b-lactam antibiotics, making it virtually impossible to
trap the acyl-enzyme intermediate for study. In class A
b-lactamase enzymes Glu166 activates the hydrolytic
water required for deacylation of the tetrahedral interme-
diate. Therefore, mutating Glu166 to an alanine halts the
reaction at the acyl-enzyme adduct (Fig. 1, stage 3)
enabling this state to be studied. The mutations R274N
and R276N prevent crystal twinning and increase
diffraction resolution [12] without dramatically affecting
the kinetics of the enzyme [13]. Tyr105 is a conserved
active-site residue throughout class A b-lactamases and
is located by the edge of the active site cavity. It has
been shown that the Y105F mutant [14,15] retains
52% catalytic efficiency toward benzyl penicillin com-
pared to wild type. This rules out a critical role for
the hydroxyl group of Tyr105 in enzyme activity,
whilst indicating that it has a role in efficiency. It has
previously been suggested that Tyr105 may stack with
the benzyl ring of penicillins [16,17] suggesting its par-
ticipation in substrate positioning within the active
site. However, to date this interaction between Tyr105
and the substrate molecule has never been shown or
directly characterized.
Materials and methods
Expression and purification of recombinant
protein
The Perdeuterated-Toho-1 E166A/R274N/R276N was puri-
fied and crystallized as described previously [18–20]. Protein
was produced to a high yield in a fully deuterated minimal
medium using a fed-batch fermentation protocol in an
Escherichia coli-based expression system [19,21]. This purifi-
cation involves cell adaptation to deuterated minimal
media, cell culture in a bioreactor, cell lysis and purifica-
tion, and finally deuterium back exchange [19]. After cell
growth in minimal media, and harvesting, pellets were
stored at 80 °C. For purification, pellets were thawed
with lysis buffer (50 mM MES pH 6.5) and protease an
inhibitor cocktail, at room temperature. Once thawed, the
cells were lysed by sonication with a Branson Digital Soni-
fier (Emerson Industrial Automation, St. Louis, MO,
USA). Lysate was then clarified by centrifugation at 34
000 g, for 45 min at 4 °C. Supernatant was filtered through
0.45 lm syringe filter (GE Healthcare, Pittsburgh, PA,
USA). Protein purification was achieved with an AKTA
purifier system (GE Healthcare), at room temperature. A
HiLoad SP Sepharose FF column (GE Healthcare) was
equilibrated with Buffer A (20 mM MES, pH 6.5), and pro-
tein was loaded onto the column. A linear gradient of buf-
fer B (20 mM MES pH 300 mM NaCl pH 6.5) was used to
elute the protein at approximately 20–30 mM NaCl. Using
UV absorbance, and SDS/PAGE gel analysis, fractions
containing pure protein were selected and pooled. These
fractions were concentrated using a 10 K MWCO Vivaspin
15R concentrator (Sartorius, Gottingen, Germany). Con-
centrated protein was loaded onto a Buffer-A-equilibrated
120-ml HiPrep Sephacryl S-100 HR gel filtration column
(GE Healthcare). Using UV absorbance, and SDS/PAGE
gel analysis, fractions containing pure protein were selected
and pooled. These fractions were concentrated using a
10 K MWCO Vivaspin 15R concentrator (Sartorius). Buf-
fer exchange was performed, and protein concentration
measured using UV absorbance, before crystallization. We
originally perdeuterated the protein for neutron studies [22]
while also using it for several X-ray studies.
Crystallization
Crystals for X-ray diffraction were grown at 20 °C via the
batch crystallization method using 30 lL of 10 mgmL1 pro-
tein concentration in a solution containing 2.0 M ammonium
sulfate and 0.1 M sodium citrate (pH 6.1). For ligand soaking,
crystals were placed for 2–3 h in a reservoir solution containing
2.7 M ammonium sulfate, 0.1 M sodium citrate (pH 6.1), and
5.0 mM benzyl penicillin. The crystals were then placed momen-
tarily in a reservoir solution containing a cryoprotectant (30%
w/v trehalose) and subsequently flash-frozen in liquid nitrogen.
Data collection and refinement
Data were collected at 15 K on a protein crystal to beyond
atomic resolution (1.10 A) on the SBC-CAT sector 19
beamline at the Advanced Photon Source. High-resolution
monochromatic data (0.67 A) were collected, using a Cryo
Industries of America (Manchester, NH, USA) cryocool
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helium cryostream at 15 K. The 15 K X-ray data were pro-
cessed using the XDS package [23], scaled using SCALA [24]
and refined with SHELX [25] to convergence. All model
building was done using the COOT molecular graphics pro-
gram [26]. Figures were created using PYMOL [27], LIGPLOT
[28], and CHEMTOOL. The data reduction and refinement
statistics for the structure are given in Table 1.
This 15 K data collection temperature produced an aver-
age mean anisotropic displacement parameter for all
protein main chain atoms of 8.50 and 12.43 A2 for the side
chain atoms. This is roughly a two-fold reduction com-
pared to similar data sets collected to the same resolution
at 100 K using a standard 100 K nitrogen cryostream.
These low displacement parameters allowed us to identify
two intact ring-closed benzyl penicillin molecules at the
edge of the active site and enabled the direct visualization
of previously unseen features of enzymatic substrate recog-
nition involving the conserved residue Tyr105.
Fig. 1. After substrate binding, Ser70 attacks the carbonyl carbon of the b-lactam ring to form an acyl-enzyme intermediate, which is then
deacylated to liberate the inactivated antibiotic. Glu166 plays a vital role in the deacylation step (stages 3–5), by acting as the activating base
of a hydrolytic water molecule. Mutating Glu166 halts the reaction at the acyl-intermediate (stage 3), allowing this state to be characterized
structurally. It has also been proposed that Glu166 acts as the catalytic base in the acylation step of the reaction (stages 1–3) by
deprotonating the hydroxyl of Ser70 via a water molecule. This allows Ser70 to attack the carbonyl carbon of the b-lactam ring.
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Results and discussion
Penicillin binding in the active site
A ring-opened penicillin molecule with a refined occu-
pancy of 94% is covalently attached to the catalytic
nucleophile Ser70 of the E166A/R274N/R276N
mutant of Toho1 b-lactamase (Fig. 2C). The carboxyl
group of the ligand is involved in hydrogen bonding
interactions with the sidechains of Thr235 (2.51 A)
and Ser237 (2.71 A) while the amino sidechain groups
of Asn132 (2.86 A) and Asn104 (3.02 A) interact with
carbonyl (O16) the hydrolyzed penicillin (Fig. 2A,B).
The main chain carbonyl group of Ser237 (2.92 A)
interacts with N14 of the ligand. The oxyanion hole
present on the carbonyl group of the ring-opened peni-
cillin is stabilized by interactions with the main chain
amide groups of Ser70 (2.74 A) and Ser237 (2.89 A;
Fig. 2A). These distances are very similar to those
observed in the acyl-enzyme complex with cefotaxime
[29], previously published by our group. In that struc-
ture the oxyanion hole stabilizing bond lengths are
Ser70 (2.78 A) and Ser237 (2.98 A) [9]. Shimamura
et al [30] proposed that differences in hydrogen bond
lengths in the oxyanion hole area between acyl-inter-
mediate structures of penicillin and acyl-intermediate
structures of cefotaxime are the reason for the lower
penicillinase activity of CTX-M type ESBL b-lacta-
mases, as the b-lactam carbonyl oxygen is not well
positioned in the oxyanion hole [30]. However, our
structures indicate that this is not the case as the
observed deviations between the penicillin and cefo-
taxime oxyanion holes are only 0.04 A for the Ser70
amide hydrogen bond and 0.09 A for the Ser237
amide hydrogen bond. These negligible bond length
differences show only a minor perturbation in the b-
lactam ring carbonyl group of the acyl-intermediate
structures of penicillin and acyl-intermediate struc-
tures of cefotaxime. We, therefore, find that that b-
lactam ring carbonyl group is well positioned in the
oxyanion hole for hydrolysis to occur, an essential
interaction for both the acylation and deacylation
reactions.
Adjacent to the active site are two intact ring-closed
penicillin molecules (PNN1 and PNN2) that are clearly
visible in electron density with refined occupancy val-
ues of 67% and 58%, respectively. They are both
coordinated by the enzyme just outside of the active
site, through noncovalent interactions (Fig. 3A). One
of these molecules, named PNN1, interacts with the
sidechain of Tyr105 at the edge of the active site in a
pi-stacking interaction with the benzyl ring of the ben-
zyl penicillin while the carbonyl group of the penicillin
molecule forms a hydrogen bond with the sidechain
amino group of Asn104 (2.83 A; Fig. 3B). This pi–pi
interaction has an inter-planar distance of 3.98 A and
an inter-planar angle of 11.5° (Fig. 3B,3D), and in
combination with the Asn104 hydrogen bond lends to
a well occupied PNN1 position (Fig. 3B). The second
ring-closed penicillin molecule, named PNN2, indi-
rectly hydrogen bonds to Asn239 through three water
molecules (Fig. 3C). These pi-stacking, and hydrogen
bonding interactions shed light into the ability of the
enzyme to attract and line up substrate molecules,
even with a PNM molecule in the active site. It should
be noted that these interactions were observed in an
inactive mutant. However, it is not possible to use pro-
tein crystallography with wild type b-lactamase
enzymes to study these interactions due to the enzymes
high catalytic rate.
Conclusions
Due to the low temperature cryocool technology,
and consequentially low average mean anisotropic
displacement parameters for all atoms in the E166A/
R274N/R276N Toho1 b-lactamase/benzylpenicillin
15 K structure, we were able to visualize for the first
time three individual drug molecules interacting with
the protein, at exceedingly high resolution. The first,
a ring-opened penicillin molecule is covalently
attached to the catalytic nucleophile Ser70, and the
close positioning of its carbonyl oxygen in the
oxyanion hole provides new support to the role of
the oxyanion hole in hydrolysis of this drug/enzyme
pair. The second, an intact ring-closed penicillin
Table 1. Data collection and refinement statistics for the X-ray
diffraction data. Values for the highest resolution bin are given in
parentheses.
PDB accession code 5KMW
Unit-cell parameters (A) a = 72.26, b = 72.26, c = 98.19
a = b = 90° c = 120°
Space group P3221
No. of unique reflections 157 550
Resolution range (A) 38.62–1.10 (1.16–1.10)
Multiplicity 5.5 (5.6)
I/r(I) 5.6 (2.1)
Rmerge (%) 9.3 (40.1)
Rpim (%) 3.8 (16.9)
Data completeness (%) 99.7 (98.6)
Crystallographic refinement
Rfactor (%) 11.52
Rfree (%) 14.34
Ramachandran plot
Outliers (%) 1.29
Favored (%) 96.78
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molecule gives evidence for substrate recognition and
binding. As originally proposed by Escobar and
Fink [14] the conserved class A b-lactamase residue
Tyr105 is involved in substrate recognition and bind-
ing. Later studies by Doucett et al. [15] used satura-
tion mutagenesis to identify the importance of
Tyr105 in substrate recognition. Our 1.10 A, 15 K,
structure of the E166A/R274N/R276N Toho1 b-lac-
tamase mutant shows the pi stacking interaction
between Tyr105 and the benzyl ring of the benzyl
penicillin substrate molecule. Tyr105 interacts with
an intact ring-closed penicillin molecule within the
active site and is clearly involved in substrate recog-
nition and binding. A second intact ring-closed peni-
cillin molecule is held in place near the active site,
by indirect hydrogen bonding to the sidechain car-
boxyl group of Asn239 through three waters. Per-
haps the ability of b-lactamase to queue up
substrate through pi–pi interaction and coordination
through direct and indirect hydrogen bonds is partly
Fig. 2. Hydrogen bonds and hydrophobic interactions between benzyl penicillin and E166A/R274N/R276N Toho1 b-lactamase mutant,
trapped in the acyl-intermediate. (A) Carbon atoms are shown in black, nitrogen in blue, oxygen in red, and sulfur in yellow. Water
molecules are indicated by turquoise spheres. The ring-opened penicillin molecule (PNM) bonds are drawn as grey lines. Enzyme bonds are
shown in brown. Hydrophobicity is indicated by a red shell around the atom or residue. Hydrogen bonds and distances (A) are shown in
green, and with dashed lines. This diagram was created using the LIGPLOT software [28]. The S70-PNM covalent bond, which traps the
reaction in the acyl-intermediate state is shown in red. (B) Hydrogen bonds between the ring-opened penicillin molecule (PNM) and enzyme
residues are indicated by black dashed lines, while the structure of both are shown as yellow sticks. Nitrogen atoms are shown in blue,
carbon atoms in yellow, sulfur atoms in gold, and oxygen atoms in red. (C) A rotated view of the active site shows the S70-PNM bond that
traps the reaction in the acyl-enzyme intermediate form.
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responsible for its effectiveness. By understanding the
intricacies of these enzymes not only within but also
just outside of the active site, we can help drive the
development of new drugs that may evade them.
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